UNSPSC 51384607: Celecoxib

This classification denotes a cyclooxygenase inhibitor with the molecular formula C17H14F3N3O2S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier JCX84Q7J1L, chemically known as benzenesulfonamide, 4-(5-(4-methylphenyl)-3-(trifluoromethyl)-1h-pyrazol-1-yl)- but generally known as celecoxib, which bears US NIH Compound Identifier 2662. European Medicines Agency schedules Celecoxib in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01143MIG.

UNSPSC 51384607 Celecoxib is a Commodity code tracking a specific pharmaceutical product, but recent state and local procurement activity under this code shows minimal direct solicitation for celecoxib itself and instead reflects broader pharmaceutical procurement initiatives. State and local governments are buying naloxone and drug deactivation systems, generic multi-source pharmaceuticals and over-the-counter products through cooperative purchasing arrangements, and exploring direct-to-manufacturer prescription fulfillment models. The issuing bodies span county health departments (Seminole County, Florida), state health and human services commissions (Texas HHS), and multistate cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance, or MMCAP). These procurements serve community health, employee health plans, and institutional pharmacy benefit programs across participating jurisdictions.

The geographic spread includes Florida, Texas, and Minnesota with expansion into Oregon through MMCAP's multistate vehicle. Representative recent opportunities include Seminole County's IFB60459723LAS seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with a July 26, 2023 response deadline (note: this date predates the posting date, indicating a data quality issue in the source); Texas HHS's RFI HHS0017013 posted April 3, 2026 to gather vendor capabilities for a Therapeutic Pharmacy Initiative direct-to-manufacturer model; and MMCAP's RFP S1070000015802 posted January 20, 2026 with a March 26, 2026 response deadline to establish multi-award contracts for generic pharmaceuticals and OTC products distributed through AmerisourceBergen, Cardinal Health, and Morris & Dickson. The code shows broad pharmaceutical procurement activity but does not reflect recent solicitations specifically targeting celecoxib as a named line item.